Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
ORGANIZATION
Cough Drug Asverin Tops Supply Shortage Ranking in Japan: P-Cubed Survey
The top three oral drugs seen by medical workers as being in short supply in Japan were all antitussive and expectorant agents, with Asverin (tipepidine hibenzate) being their biggest headache, according to a survey conducted by Pharma Policy Planning (P-Cubed).…
To read the full story
ORGANIZATION
- FPMAJ Maps Out Planned Activities for FY2025
March 24, 2025
- JEMA Proposing “Improved Drug” Category with Minimal Application Dossiers
March 10, 2025
- Cough Drug Asverin Tops Supply Shortage Ranking in Japan: P-Cubed Survey
March 6, 2025
- JPMA President Demands Rethink of Social Security Expenditure Cap
February 27, 2025
- People’s Trust in Pharma Industry Down to 83.9% in 2024: JPMA Poll
February 27, 2025
The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…